CIK 0001840233
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 851623397
- Phone
- +1 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-26 | RiverVest Venture Fund IV, L.P. 10% owner | Purchase | +250,000 | $16.00 | $4.0M | 1,441,444 |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. 10% owner | Conversion · Series B Preferred Stock | −832,120 | 0 | ||
| 2021-10-26 | RiverVest Venture Fund IV, L.P. 10% owner | Conversion · Series B Preferred Stock | −359,324 | 0 | ||
| 2021-10-21 | Russo Rene CEO and President | Grant or award · Stock Option (right to buy) | +50,041 | 50,041 | ||
| 2021-10-21 | Ross Michael Jay Director | Grant or award · Stock Option (right to buy) | +26,400 | 26,400 | ||
| 2021-10-21 | Huber Martin H. Jr. President of R&D and CMO | Grant or award · Stock Option (right to buy) | +157,058 | 157,058 | ||
| 2021-10-21 | Giovine Salvatore Chief Financial Officer | Grant or award · Stock Option (right to buy) | +28,755 | 28,755 |
Page 13 of 13 · 247 trades